A LinkedIn post from Koios Care indicates that the company has obtained ISO 13485:2016 certification for its quality management system. The certification is presented as a key step for its AI-driven Software as a Medical Device, specifically the PARKIWATCH digital health solution for Parkinson’s disease management.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that this milestone is intended to underpin future regulatory approval efforts and eventual market deployment to patients. For investors, achieving ISO 13485 may reduce regulatory-risk hurdles, potentially shortening time-to-market and improving Koios Care’s credibility with healthcare providers and partners in the medtech and digital health sectors.
The focus on quality standards in AI-based medical software could position Koios Care more favorably against competitors lacking comparable certifications. If the company successfully progresses from certification to regulatory clearance and commercialization, this groundwork may support future revenue generation and strategic collaborations in the Parkinson’s disease care ecosystem.